Expert Ratings for Harmony Biosciences
Portfolio Pulse from Benzinga Insights
Harmony Biosciences (NASDAQ:HRMY) has received positive analyst ratings in the last quarter, with 6 bullish and 4 somewhat bullish ratings. The average 12-month price target for the company is $66.3, an increase of 0.96% from the previous average of $65.67.
August 22, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harmony Biosciences has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. In this case, the positive ratings for Harmony Biosciences indicate a favorable outlook for the company, which could lead to increased demand for the stock and a potential rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100